A Phase 1/2, Open-label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study.
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Bortezomib (Primary) ; Busulfan; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 03 Jun 2013 Planned End Date changed from 1 Mar 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 14 Dec 2010 New trial record